Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean angeles willett[Author] (66 results)?
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Huey RW, et al. Among authors: willett a. J Natl Cancer Inst. 2023 Aug 8;115(8):994-997. doi: 10.1093/jnci/djad095. J Natl Cancer Inst. 2023. PMID: 37202363 Free PMC article. Clinical Trial.
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.
Hornstein NJ, Zeineddine MA, Gunes BB, Pellatt AJ, Knafl M, Zhu H, Willett AF, Yousef A, Liu S, Sun R, Futreal A, Woodman SE, Taggart MW, Overman MJ, Halperin DM, Raghav KP, Shen JP. Hornstein NJ, et al. Among authors: willett af. Cancer Res Commun. 2024 May 29;4(5):1363-1368. doi: 10.1158/2767-9764.CRC-24-0019. Cancer Res Commun. 2024. PMID: 38709066 Free PMC article. Clinical Trial.
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.
Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Raghav KP, et al. Among authors: willett af. J Immunother Cancer. 2022 May;10(5):e004822. doi: 10.1136/jitc-2022-004822. J Immunother Cancer. 2022. PMID: 35618285 Free PMC article. Clinical Trial.
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.
Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A Jr, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Raghav K, et al. Among authors: willett a. Clin Cancer Res. 2021 Jun 15;27(12):3414-3421. doi: 10.1158/1078-0432.CCR-20-4117. Epub 2021 Apr 15. Clin Cancer Res. 2021. PMID: 33858857 Free PMC article.
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Raghav K, et al. Among authors: willett af. Cancer Discov. 2021 Nov;11(11):2738-2747. doi: 10.1158/2159-8290.CD-21-0331. Epub 2021 Jul 14. Cancer Discov. 2021. PMID: 34261675 Free PMC article.